Emmaus Life Sciences Inc. will likely need the US FDA's Oncologic Drugs Advisory Committee to save the day for the company's sickle cell disease candidate L-glutamine, as the agency itself appears deeply skeptical of the Emmaus' method for extrapolating efficacy data to substitute for a high discontinuation rate.
The Torrance, Calif.-based drugmaker saw a higher than expected dropout rate in the treatment arm of its main Phase III...




